Since the combination of IRAK1/4 inhibitor and imatinib attenuates PD-L1 expression on CML LSCs, the combination also induces T cell antitumor immunity in addition to its proapoptotic activity. This evidence concerns the gene IRAK1 and chronic myelogenous leukemia, BCR-ABL1 positive.